NEW YORK (GenomeWeb) – Interpace Diagnostics today announced that an independent Blue Cross Blue Shield plan has begun covering the firm's ThyGenX Thyroid Oncogene Panel and ThyraMIR Thyroid miRNA Classifier, molecular tests for indeterminate thyroid nodules. 

Interpace, a subsidiary of PDI, did not identify the BCBS plan but said that it insures 3.3 million lives and added that it is the first commercial plan to cover ThyraMIR, a microRNA gene expression classifier launched earlier this year for identifying indeterminate benign and malignant thyroid nodules. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.